Clinical Trial Update: A Study To Investigate The Effect Of 28 Days Of Dosing With GW856553 On Patients With Rheumatoid Arthritis [Phase 2]

View source ↗

Summary

A Phase 2 study evaluating the effects of 28 days of dosing with GW856553 in patients with rheumatoid arthritis; the trial sponsored by GlaxoSmithKline has comp…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Rheumatoid Arthritis

Drugs mentioned

• GW856553

Snippet

Sponsor: GlaxoSmithKline | Conditions: Arthritis, Rheumatoid | Phase 2 | Status: COMPLETED